Spring Builders: thomas schmitt

Flow Cytometry Antibodies to Advance Non-Human Primate Research

thomas schmitt — Thu, 28 May 2026 07:22:35 +0000

Although non-human primates account for only a small proportion of the animals used in biomedical research, they remain important research models due to their high degree of similarity to humans in terms of genetic makeup, anatomy, physiology and behaviour. Key medical advances have been driven by research conducted using non-human primates, primarily monkeys, saving or improving the lives of millions of people.

Prior to clinical trials, NHP models play a crucial role in evaluating therapeutic antibodies, biologics, and immunomodulatory drugs. Flow cytometry has become an essential analytical tool for studying immune responses in these models. Enabling high-dimensional analysis of immune cell populations and their activation states, it allows researchers to assess changes in immune cell subsets, functional markers, and cytokine expression in response to drug candidates, vaccines, or disease progression.

However, researchers often face a significant challenge in the form of the limited availability of antibodies that are specifically validated to target monkey immune markers. This means that many laboratories are forced to rely on anti-human antibodies that exhibit cross-reactivity, which can lead to inconsistent results, weak signals or poor reproducibility.

To address this issue, Creative Diagnostics has developed a portfolio of high-quality antibodies that target monkey immune cell surface markers specifically. These antibodies enable precise immune monitoring and support the reliable phenotyping of non-human primate immune systems and translational research.

Creative Diagnostics' rabbit anti-monkey flow cytometry antibody panel has been developed to detect surface markers on monkey immune cells. Designed to support preclinical pharmacology studies, immune profiling and mechanistic research in non-human primate models, these antibodies help pharmaceutical and biotechnology companies to accelerate the development of innovative therapies.

The panel enables precise characterization of immune cell subsets and signaling pathways involved in drug responses, disease progression, and immune regulation in NHP research. The broad coverage of markers allows researchers to construct multiparametric flow cytometry panels and facilitates in-depth immunophenotyping analyses in non-human primates.

Furthermore, these antibodies have been optimized to exhibit high specificity for non-human primate antigens, enabling the accurate detection of primate immune markers with minimal background signal. All the antibodies in this panel are produced using recombinant antibody technology and demonstrate an excellent signal-to-noise ratio.

These rabbit anti-monkey flow cytometry antibodies are ideal for various applications in NHP research, including preclinical drug development, immunophenotyping, mechanism of action studies and safety and immunotoxicity assessments. For more information about the Rabbit Anti-Monkey Flow Cytometry Antibody Panel or to view the full product catalog, please visit https://www.creative-diagnostics.com/flow-cytometry-antibodies-for-non-human-primate-research.htm.

About Creative Diagnostics

Creative Diagnostics is a leading manufacturer and supplier of antibodies, viral antigens, innovative diagnostic components, and critical assay reagents. In addition to providing contract R&D and biologic manufacturing services for diagnostic manufacturers along with GMP biologics manufacturing for the biopharmaceutical market, the company aims to continue to act as a trusted source for all researchers’ assay development and manufacturing needs.

Preclinical Support with Advanced Coronavirus Animal Model Services for Antiviral Research

thomas schmitt — Mon, 25 May 2026 05:46:54 +0000

The Coronavirus Disease 2019 (COVID-19) pandemic has led to the rapid development of animal models to help us understand the disease's pathogenesis, test treatments and support vaccine development. Models previously established for studying severe acute respiratory syndrome coronavirus (SARS-CoV) have been rapidly adapted for SARS-CoV-2 research. However, despite both viruses utilizing ACE2 as their receptor, it is clear that their host ranges do not fully overlap. SARS-CoV and SARS-CoV-2 have different residues that interact with ACE2 within their receptor-binding domains. Furthermore, there are species-specific differences in the proteases required for viral activation and internalization, which are likely responsible for the differences in host range between the two viruses. Natural host models include rhesus macaques, long-tailed macaques, African green monkeys, hamsters and ferrets.

Animal models are an indispensable component of research into COVID-19. While in vitro, ex vivo and organoid models have revealed key virological characteristics of SARS-CoV-2, animal models that can reproduce the clinical and pathological features of human COVID-19 are essential for investigating the virus's pathogenic mechanisms, transmission routes, potential therapeutics and vaccines. Insights into pathogenic mechanisms and virus-host interactions derived from in vitro studies require validation through animal models to confirm their physiological relevance. Novel antiviral drugs must be evaluated in animal models because characteristics such as bioavailability, serum concentrations, half-lives and tissue distribution can only be assessed in vivo. Similarly, transmission and vaccine research can only be evaluated using physiologically relevant animal models.

Creative Diagnostics is dedicated to delivering innovative solutions for studying coronaviruses, including developing and applying animal models. Drawing on its extensive experience in this field, Creative Diagnostics offers a comprehensive range of services to support research into animal models of coronaviruses, specifically tailored to the needs of researchers and pharmaceutical companies. These services include study design and execution, pathological analysis and immune response profiling, and the efficacy testing of vaccines and antiviral compounds, as well as data analysis and interpretation.

While a variety of animal models are currently available, none can fully replicate all the pathological features of human Coronavirus infection. Creative Diagnostics' research team has an in-depth understanding of the strengths and weaknesses of various animal models, and can optimize them to help researchers achieve their scientific objectives. The Coronavirus animal models include SARS-CoV Virus Intranasal Infection Rhesus Monkey Model, SARS-CoV Virus Intranasal Infection Mouse Model, and SARS-CoV-2 Syrian Hamster Model.

For more information regarding the Coronavirus Animal Model services or to request a project consultation, please visit https://antiviral.creative-diagnostics.com/coronavirus-animal-model.html.

SpeX™ Gerbillinae Liver Microsomes to Advance In Vitro Drug Metabolism Research

thomas schmitt — Fri, 22 May 2026 02:46:00 +0000

The Gerbillinae subfamily is the second largest within the Muridae family, after the Murinae subfamily, comprising approximately 16 genera and over 100 species. The phylogenetic relationships among the major clades within the Gerbillinae remain unclear. One of the main issues concerns the phylogenetic position of the monotypic genus Ammodillus, which is endemic to the Horn of Africa. Based on morphological data, this genus may represent one of the earliest branches of the Gerbillinae main clade. However, due to a lack of genetic data, its precise taxonomic placement has not yet been determined.

The Gerbillinae subfamily includes gerbils and sand rats, both of which are adapted to arid and semi-arid environments. Species within this subfamily possess highly efficient water conservation capabilities, unique metabolic regulation mechanisms, and physiological adaptations. These characteristics distinguish them from commonly used laboratory rodents, such as mice and rats.

In drug research, species of the Gerbillinae subfamily play a vital role as valuable preclinical research models. Their unique cerebral vascular anatomy makes them particularly well-suited to studies of cerebral ischaemia, stroke, and neuroprotective therapies. Furthermore, Gerbillinae models are widely used in neuroscience, auditory research, epilepsy research and infectious disease research, as the progression of disease and pharmacological responses they exhibit often more closely mirror those observed in humans.

From a pharmacological perspective, species in the Gerbillinae subfamily have unique characteristics that influence drug efficacy, pharmacodynamics, and metabolism under various physiological conditions. Differences in their metabolic pathways and tissue sensitivity provide important insights into species-specific drug responses, helping to bridge the gap between traditional rodent models and human translational research. Consequently, Gerbillinae models are playing an increasingly important role in innovative drug discovery and translational research.

Drawing on years of expertise in the field of in vitro biological reagents, Creative Diagnostics has developed the SpeX™ Gerbillinae liver microsome model to support researchers' drug metabolism studies. The launch of the model enables scientists to utilize these unique metabolic characteristics within a controlled, high-throughput in vitro environment.

These new liver microsomes have been carefully developed to provide a reliable and translationally relevant in vitro model that supports research into cholesterol metabolism, diabetes, neuroprotection, epilepsy, and the development of anti-parasitic drugs. For more information about SpeX™ Gerbillinae Liver Microsomes or to explore the full range of ADME products and services, please visit https://qbd.creative-diagnostics.com/spex-gerbillinae-liver-microsomes.html.

About Creative Diagnostics

Creative Diagnostics is a global leader in the development and manufacturing of innovative tools and reagents for bioprocess impurity analysis. The company offers a comprehensive portfolio of solutions to support researchers in the quality control of biologics and provides biopharmaceutical quality, purity and safety assays, analytical methods and applications for the biotechnology and biopharmaceutical industries.